Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Current Technologies’ Bio-Hazard wipes protect patients and employees from cross-contamination when opening and handling specimen containers and sputum cups. The white side of the Bio-Hazard wipe absorbs specimen contents and sputum, while the orange plastic backing prevents splash or leakage from containers to gloves.
Horizon Discovery has entered into a nonexclusive license agreement with Sigma-Aldrich for use of its CompoZr zinc finger nuclease (ZFN) technology.
BD Diagnostics announced FDA clearance of its BD ProbeTec Trichomonas vaginalis Qx amplified DNA assay for the direct qualitative detection of T. vaginalis DNA in endocervical samples, vaginal samples, and neat urine specimens. This assay, developed to aid in the diagnosis of trichomoniasis, has been CE marked to the in vitro diagnostic directive.
SeraCare Life Sciences has acquired Kirkegaard & Perry Laboratories (KPL), a provider of antibodies and related reagents for the diagnostic and life sciences markets.
Thermo Fisher Scientific’s ImmunoCAP peanut component tests are now available through Quest Diagnostics. Unlike skin scratch testing, the ImmunoCAP peanut component tests measure a patient’s IgE sensitization to five individual peanut proteins, or allergen components.
BioTheranostics, a provider of molecular diagnostic solutions for cancer, has received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerType ID molecular cancer classifier. CancerType ID predicts tumor type in patients with metastatic cancers.
Diagnostica Stago offers expertise through two free electronic resources to educate health care professionals about hemostasis and thrombosis. The Stago-EdVantage Web site and iHemOStasis app for the Apple iPad offer ways to increase hemostasis knowledge; understand clinical situations, therapies, and detection methods; and apply practical skills to patient care.
Illumina and Natera announced they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq 2500 sequencing system and associated consumables for performing Natera’s noninvasive prenatal test (NIPT) Panorama.
Audit MicroControls’ Linearity FD General Chemistry Beckman AU simulates human patient serum samples for determining linearity, calibration verification, and verification of reportable range for albumin, alkaline phosphatase, ALT, total amylase, AST, total bilirubin, direct bilirubin, BUN, calcium, chloride, cholesterol, CO2, creatine kinase, creatinine, gamma-GT, glucose, iron, lactate, LDH, lipase, magnesium, phosphorous, potassium, sodium, total protein, triglycerides, and uric acid. This five-level lyophilized product, packaged as 10 × 5 mL, has a shelf life of two years and open-vial stability of seven days when stored at 2°C to 8°C.
A new study, conducted by researchers at the John A. Burns School of Medicine, University of Hawaii, and published in the Journal of Microbiology, evaluated the InBios DENV Detect IgM capture ELISA for qualitative detection of IgM antibodies to dengue virus recombinant antigens. Well-characterized clinical serum samples collected from Hawaii, Vietnam, Niue, Singapore, and American Samoa were tested with the InBios ELISA in comparison with an in-house DENV IgM antibody capture (MAC) ELISA. The agreement, sensitivity, and specificity of the InBios assay were 94, 92, and 94 percent, respectively.
